JP2022524741A5 - - Google Patents

Info

Publication number
JP2022524741A5
JP2022524741A5 JP2021552142A JP2021552142A JP2022524741A5 JP 2022524741 A5 JP2022524741 A5 JP 2022524741A5 JP 2021552142 A JP2021552142 A JP 2021552142A JP 2021552142 A JP2021552142 A JP 2021552142A JP 2022524741 A5 JP2022524741 A5 JP 2022524741A5
Authority
JP
Japan
Prior art keywords
selinexol
succinic acid
cocrystal
mixed solution
morphology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021552142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023530 external-priority patent/WO2020191140A1/en
Publication of JP2022524741A publication Critical patent/JP2022524741A/ja
Publication of JP2022524741A5 publication Critical patent/JP2022524741A5/ja
Priority to JP2025106508A priority Critical patent/JP2025134935A/ja
Pending legal-status Critical Current

Links

JP2021552142A 2019-03-20 2020-03-19 セリネクソールの共結晶形態 Pending JP2022524741A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025106508A JP2025134935A (ja) 2019-03-20 2025-06-24 セリネクソールの共結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821203P 2019-03-20 2019-03-20
US62/821,203 2019-03-20
PCT/US2020/023530 WO2020191140A1 (en) 2019-03-20 2020-03-19 Co-crystal forms of selinexor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025106508A Division JP2025134935A (ja) 2019-03-20 2025-06-24 セリネクソールの共結晶形態

Publications (2)

Publication Number Publication Date
JP2022524741A JP2022524741A (ja) 2022-05-10
JP2022524741A5 true JP2022524741A5 (https=) 2024-11-18

Family

ID=70293085

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552142A Pending JP2022524741A (ja) 2019-03-20 2020-03-19 セリネクソールの共結晶形態
JP2025106508A Pending JP2025134935A (ja) 2019-03-20 2025-06-24 セリネクソールの共結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025106508A Pending JP2025134935A (ja) 2019-03-20 2025-06-24 セリネクソールの共結晶形態

Country Status (8)

Country Link
US (1) US12559478B2 (https=)
EP (1) EP3941588A1 (https=)
JP (2) JP2022524741A (https=)
KR (1) KR20210141936A (https=)
CN (1) CN113423468A (https=)
BR (1) BR112021016762A2 (https=)
CA (1) CA3130107A1 (https=)
WO (1) WO2020191140A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016762A2 (pt) 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104230936A (zh) * 2009-12-03 2014-12-24 阿斯利康(瑞典)有限公司 三唑并[4,5-d]嘧啶血小板聚集抑制剂的共晶体
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
US9808450B2 (en) * 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
US20180230140A1 (en) * 2014-06-30 2018-08-16 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
EP3565813A1 (en) * 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN107089946B (zh) * 2017-05-05 2020-04-03 浙江科技学院 一种诺氟沙星与香兰素共晶及其制备方法
BR112021016762A2 (pt) 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor

Similar Documents

Publication Publication Date Title
JP7100625B2 (ja) 置換２－ｈ－ピラゾール誘導体の結晶形、塩型及びその製造方法
CN115461344B (zh) 一种glp-1受体激动剂的晶型a及其制备方法
CN114209699A (zh) C-met调节剂药物组合物
CN101676266B (zh) 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
TWI675839B (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
CN108779126A (zh) 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物的结晶形式
CN107427503A (zh) 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
JP2019504033A (ja) 選択的なｓ１ｐ１受容体アゴニストの新規な結晶形及びその製造方法
KR102886764B1 (ko) Cdk9 억제제의 결정다형 및 이의 제조방법과 용도
EP3626715A1 (en) Crystal of benzofuran derivative free base and preparation method
TW201629060A (zh) 一種週期素依賴性蛋白激酶抑制劑的羥乙基磺酸鹽、其結晶形式及製備方法
TW201638090A (zh) 一種週期素依賴性蛋白激酶抑制劑的結晶形式及其製備方法
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
WO2023078451A1 (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN117529313A (zh) 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐
EP3430004A1 (en) Solid state forms of nilotinib salts
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
JP2022524741A5 (https=)
JP2024530315A (ja) Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法
CN108884099B (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
JP6761564B2 (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
AU2016318700B2 (en) Crystalline form of androgen receptor inhibitor and preparation method thereof
US20210395232A1 (en) Co-crystal forms of selinexor
JP2022524011A (ja) 化合物結晶形、その製造方法、医薬組成物及び使用
HK40072576B (zh) 用作激酶抑制剂的化合物及其应用